{"name":"Center For Sight","slug":"center-for-sight","ticker":"","exchange":"","domain":"","description":"","hq":"","founded":0,"employees":"","ceo":"","sector":"","stockPrice":0,"stockChange":0,"stockChangePercent":0,"marketCap":"","metrics":{"revenue":0,"revenueGrowth":0,"grossMargin":0,"rdSpend":0,"netIncome":0,"cash":0,"dividendYield":0,"peRatio":0,"fiscalYear":"FY2026"},"revenueBreakdown":[],"timeline":[{"date":"2026-07-28","label":"Q2 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2026-10-28","label":"Q3 2026 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-01-28","label":"Q4 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-04-28","label":"Q1 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-07-28","label":"Q2 2027 Earnings","type":"earnings","sentiment":"neutral"},{"date":"2027-10-28","label":"Q3 2027 Earnings","type":"earnings","sentiment":"neutral"}],"diseaseAreas":[{"name":"Ophthalmology","slug":"ophthalmology","revenue":0,"percentOfTotal":0,"drugCount":1,"colorKey":"oncology","drugs":[{"name":"acoltremon 0.003%","genericName":"acoltremon 0.003%","slug":"acoltremon-0-003","indication":"Dry eye disease (marketed formulation)","status":"marketed"}]}],"pipeline":[{"name":"acoltremon 0.003%","genericName":"acoltremon 0.003%","slug":"acoltremon-0-003","phase":"marketed","mechanism":"Acoltremon is a topical retinoid that modulates retinoid receptor signaling to promote corneal epithelial healing and reduce inflammation.","indications":["Dry eye disease (marketed formulation)"],"catalyst":""}],"recentEvents":[],"realNews":[{"url":"https://news.google.com/rss/articles/CBMiXEFVX3lxTFB1N2d4NnYwN0JiU181Tm9vV0dUM1c1NWVMUHNCdlZFVmRSZXpmRFp3TnBQUVJXYnFYV1VlNVBIZXU0TzY4bE5BNTd4NGpIT21aYlZHMy1qSW1HWDFH?oc=5","date":"2026-04-06","type":"pipeline","source":"BioSpace","summary":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees - BioSpace","headline":"Layoff Tracker: BioNTech Will Close Singapore Plant, Affecting 85 Employees","sentiment":"neutral"},{"url":"https://news.google.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?oc=5","date":"2026-03-31","type":"pipeline","source":"Al Jazeera","summary":"Cancer drug facility, religious site hit in Israeli-US strikes on Iran - Al Jazeera","headline":"Cancer drug facility, religious site hit in Israeli-US strikes on Iran","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMinAFBVV95cUxNSllhQmxMeWNGb05zY2NaamJSdlp2RDU5WVVMNEpleFgwd0JfMS01aFg5bTV2M0YydW8zcHBDVEk1VXZuaEk4aG5aWEVHeS1sc0NHd0UyZEowa3JmS3RXVU0tVUJYMXotaHpGOTd5eDJwMGc3WFVlNl9ZSXlKQ1BOQTZjdjhyaENOWTVVNndLWEJXOTIyaFpxVVBFVGc?oc=5","date":"2026-03-13","type":"pipeline","source":"Crowell & Moring LLP","summary":"The EU Pharma Package: Formal Adoption in Sight - Crowell & Moring LLP","headline":"The EU Pharma Package: Formal Adoption in Sight - Crowell & Moring LLP","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqAFBVV95cUxNaFJYMkhycXFJX2ZvUk9ZNjh0Y3I3MHAwX0lUT09vci1zX2VfeWxPWFRQc3dBR2xFMjY3ZTBPaXRxZGoxb2FPMzY1VGN3YzRyai1nM0lrOWlZYTlRMEJlMDQyajg0eUM2enpjbDJDZE9PVVlLLS11Q01fNlJmZUNYQ1d2NnE1a3l6VDFQYkxLeHBONEhIbG1ocm1pZTdROGUxZVlJc2p6R0w?oc=5","date":"2026-02-11","type":"trial","source":"Endpoints News","summary":"More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem - Endpoints News","headline":"More data, costly standards and no end in sight: Pharma grapples with its clinical trials cost problem","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMidkFVX3lxTE4zOU1zT01IMG93R2NSMVZZMUVTS0l6N1Bybksza0FjM2U4N2JILVllMWVuZjRNMlpZYjI1a1Q1YTNpN09lUWdWek9ENWUwbktFampnWkl2dU5iend4SW0ydDZVWFdWUmYweFc3bUVtS1R5WDFsdGc?oc=5","date":"2026-01-15","type":"earnings","source":"Modern Healthcare","summary":"JPM 2026, Day 4: Clover predicts a profit, plans tech investments - Modern Healthcare","headline":"JPM 2026, Day 4: Clover predicts a profit, plans tech investments","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiqgFBVV95cUxQeEZsbG5qRklhbTJ1MVNZREh0NE5SLXppZ25mQ2l5c19ZbHk3NzF3eEJsZVdqX0VVd3BJRmZObmNWRFI1aWpCb2pQdlh1MjFKN2RyaXJVMzI2cVJENWtuUTZaOEJmaHp2dnBxMjN6YVdRVElYMmpoaGQwRmd5V1hZZDdxSDQteHZtZVpkZjFOY19fXzJPV0hoQk02VEZXeDA4R2pTWTA5NXZTZw?oc=5","date":"2025-12-29","type":"trial","source":"Ophthalmology Times","summary":"PRIMAvera study: Central vision improvement with subretinal implant - Ophthalmology Times","headline":"PRIMAvera study: Central vision improvement with subretinal implant","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiX0FVX3lxTE1vTHFTYW13ZVA0M21hVFRXTFBJMEg3TUhXaDB6MWFvVlJucVpOMnNaWEZnWmt6bjlPZGNZVWNWR2tDUnhiZ1JQcWxjcDZhRXdTTGFGX3pFdU1WRnJnN2Zr?oc=5","date":"2025-12-05","type":"trial","source":"Nature","summary":"Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study - Nature","headline":"Proportion of patients with Demodex blepharitis in ophthalmology clinics in Europe: the Eos study","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMiiwFBVV95cUxQM2RlTm9PQTdxN0QxZVk5VEpNOHV2ZnFvZml6WTN2OHRPNm55VVFYejlDX1hVdXJUZ091TGpKdFZPVzRJcEstaVVRY2RFT1E5ajB0ems5MnByQnR4OFBsaU9hREtrVHJMM1E4Zm9hcjdtck5tU0JsaDRqbVJkSmR0b3JwT1VVSGpDQWlr?oc=5","date":"2025-09-22","type":"regulatory","source":"CHEManager","summary":"Prange Pharma Acquires Site in Italy from MSD - CHEManager","headline":"Prange Pharma Acquires Site in Italy from MSD","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMipAFBVV95cUxPM3ZpUnV0WEFzakkzQ3lHVXlhTFpzYkpOdEFmOGxGOU5UdjNNRVpfYUFEbHhCcXZhRGd3bFRXZWY5WDZVSTFiMklqTFdCY1R4ZnBLdlVBcTB1MFR4TnR4UHhJYXpzdkpTcDhia2wwS0QxS2FNeDNCS0RMOEV0a1V6T1lPbERqTnNWQW1MY194M1BMNHpIeW9BVTAzWWwyNDl1ck9hWA?oc=5","date":"2025-08-28","type":"pipeline","source":"Healio","summary":"Breakthrough therapies in dry eye limited by access - Healio","headline":"Breakthrough therapies in dry eye limited by access","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMijwFBVV95cUxQRkxHQndtV3RMVUxBSlp0eFRaSTV2NHdVOXhfajRhNFRXT3B4cmV1RkZ0Vm01U1Q2S0p0REZoNnUyUXkwOHJNdXJKQmluLUhldVMxWlVzRk9SU1BNSEUyVWs1enFFTmJvZE1QUl92UlFpeW4yTFB3SzZlSlpjM1VLcnlHMHN3a3VvZVcxNTNlaw?oc=5","date":"2025-07-16","type":"pipeline","source":"PwC","summary":"Medical cost trend: Behind the numbers 2026 - PwC","headline":"Medical cost trend: Behind the numbers 2026","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMi-gFBVV95cUxOUUtGa1h3QXZSczIwcDdiNTVGd1oydGVWRUZvY0lKdHNQV0hQU2ZMeWd1STlmMVM4ZDVVNkptdVZkN3hfOGRySVpXSnlFbk1LUDZzcjZ0UHo2REhkOEF4SUVTR19QcmJfYmpFcjNFVzRWSl9KM1JuRllhSS05S3NpWVdLS3pmZlhDRUNSZ092eWNBM0NNX2xpWEJFVzZtaGJ3bFV5eV9TeXVqVldicEFCLTdsTVBiY195NjQ0dzZ1RS1wZUd4enJsZ1doc2tZMnBmSjltWkxfelJKVG83T2YzMmRpenpwR2ZFZndHZlE0blpoMl9aTnRNZzNR?oc=5","date":"2024-12-19","type":"pipeline","source":"City of Huntsville (.gov)","summary":"Global ophthalmic pharmaceutical and medical technology company, Glaukos, to locate multimillion-dollar facility in Cummings Research Park - City of Huntsville (.gov)","headline":"Global ophthalmic pharmaceutical and medical technology company, Glaukos, to locate multimillion-dollar facility in Cumm","sentiment":"neutral"},{"url":"https://news.google.com/rss/articles/CBMisAFBVV95cUxOMmk0RHBtaENzckNYSW9YQTA4QXJhbXNlcE5JdlBrX1dXenJzeFBueGU1ZzQ2ZXpIMFc3MmtRQ3BfX1lnSTlLb1lnM1JSWllKM3Eyb0lzNE5ua255SWluanFsNGo3RFljb2gxTWtnb1p2ZWlhMVZLUmV6TFozWTZQVDNLRm5ReWN1QzhEa0J1NG02dnZlR19xVmFZcjNXQjg4ZlFWdEx1RlFua1RiOGk0Mg?oc=5","date":"2023-03-14","type":"regulatory","source":"University of California - Davis Health","summary":"FDA warns people not to use 2 types of eye drops due to contamination - University of California - Davis Health","headline":"FDA warns people not to use 2 types of eye drops due to contamination - University of California","sentiment":"neutral"}],"patents":[],"drugCount":1,"phaseCounts":{"marketed":1},"enrichmentLevel":0,"visitCount":1,"keyCompetitors":[],"therapeuticFocus":[],"financials":null,"yahoo":null}